glp-1 receptor antagonist Frontiers GLP1 Receptor Agonists—Effects beyond Obesity

These opposing effects might seem like they would cancel each other out

Initiation rates for ADM GLP-1 RA are about the same in March 2025, relative to December 2024 (+4.2%)

"The potential increase was smallfewer than one additional case per 2,000 GLP-1RA users, while these medications have very well-established benefits for diabetes, obesity, and heart and kidney health

A licensed provider makes the final clinical determination

Prebiotics, including galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), and xylo-oligosaccharides, are nondigestible substrates that selectively stimulate the growth or activity of beneficial microbes (Ansari et al., 2023